Quick Answer
BIOGEN INC. reported R&D Expense of $1.33 billion for fiscal year 2012.
BIOGEN INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2012 | $1.33B | +9.5% |
| 2011 | $1.22B | -2.3% |
| 2010 | $1.25B | -2.7% |
| 2009 | $1.28B | +19.7% |
| 2008 | $1.07B | +15.9% |
| 2007 | $925.16M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2013 | $284.34M | -20.1% | -6.5% |
| September 30, 2012 | $304.22M | +0.9% | -7.7% |
| June 30, 2012 | $329.56M | +15.4% | -7.4% |
| March 31, 2012 | $355.96M | +21.2% | +18.1% |
| September 30, 2011 | $301.39M | -5.5% | +5.5% |
| June 30, 2011 | $285.64M | -13.9% | -2.7% |
| March 31, 2011 | $293.63M | -4.4% | -8.0% |
| September 30, 2010 | $319.05M | +4.9% | -3.8% |
- BIOGEN INC. showed an increase of +9.5% in R&D Expense compared to the prior fiscal year.
- Over the 2007–2012 period, BIOGEN INC.’s r&d expense has grown by 44.3% (from $925.16 million to $1.33 billion).
- The most recent figure is from BIOGEN INC.’s fiscal year 2012 report (Form 10-K), filed with the SEC on February 5, 2013.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: